![]() |
|
|
Vol. 290, Issue 2, 761-767, August 1999
Department of Physiology and Pharmacology, The University of Queensland, Brisbane, Queensland, Australia (F.A.P., L.J.B.-L., P.P.) and Department of Pharmacology and Toxicology, University of Bonn, Bonn, Germany (P.P., M.B., H.B.)
| |
Abstract |
|---|
|
|
|---|
The aims of this study were to characterize the recently cloned rat norepinephrine transporter (NET) in more detail and in particular to study possible species differences in its pharmacological properties compared with the human and bovine NETs. The study was carried out by measuring the uptake of [3H]norepinephrine in COS-7 cells expressing the NET after transient transfection with rat, human, or bovine NET cDNA. There were small but significant differences between the rat NET and the human or bovine NETs with respect to the affinities of sodium ions (greater for rat than for bovine) of the substrates norepinephrine, epinephrine, and 1-methyl-4-phenylpyridinium (greater for human than for rat), and of the inhibitor cocaine (greater for human and bovine than for rat), whereas the affinities of dopamine and of most inhibitors, including tricyclic antidepressants, showed no species differences. The fact that the affinities for some substrates, cocaine and sodium ions exhibited small but significant interspecies differences among the rat, human, and bovine NETs suggests that ligand recognition, the translocation process, and sodium ion dependence are influenced differentially by just a few amino acid exchanges in the primary sequences of the transporters. On the other hand, the lack of any major differences in the pharmacological properties of the rat, human, and bovine NETs in this study suggests that data obtained in previous studies on rat tissues and bovine cells can be extrapolated, in all except the most quantitative analyses, to the properties of the human NET.
| |
Introduction |
|---|
|
|
|---|
The
termination of chemical signaling at monoaminergic synapses occurs by
uptake of the neurotransmitter into the neuron by transporters
belonging to the gene family of Na+- and
Cl
-dependent monoamine neurotransmitter
transporters (for reviews, see Amara and Kuhar, 1993
; Bönisch and
Brüss, 1994
; Borowsky and Hoffman, 1995
). Expression cloning of
the human norepinephrine transporter (NET; Pacholczyk et al., 1991
) was
followed by homology cloning of the rat dopamine transporter (DAT;
Kilty et al., 1991
; Shimada et al., 1991
) and the rat serotonin
(5-hydroxytryptamine) transporter (SERT; Blakely et al., 1991
; Hoffman
et al., 1991
). These transporters for monoamines form a subfamily
within the superfamily of neurotransmitter transporters. Common
features of these monoamine transporters are their
Na+ and Cl
dependence, 12 transmembrane spanning domains (TMDs) as predicted by hydrophobicity
analysis, intracellular N and C termini, and a large extracellular loop
between TMD3 and TMD4 (see reviews as above). Substrates for the NET
include the endogenous catecholamines (
)-norepinephrine and
(
)-epinephrine and dopamine, the neurotoxin 1-methyl-4-phenylpyridinium (MPP+), and the
psychostimulant amphetamine (Bönisch and Brüss, 1994
). NET
inhibitors include tricyclic antidepressants such as desipramine and
the psychostimulant cocaine (Bönisch and Brüss, 1994
). The NET is critical for removal of neurotransmitter norepinephrine from the
synaptic cleft and maintaining noradrenergic homeostasis. The human NET
gene is therefore one of the candidate genes that may be involved in
the pathogenesis of various psychiatric disorders, including depression
and schizophrenia (Borowsky and Hoffman, 1995
). NET is also expressed
in non-neuronal tissues in which it is responsible for the removal of
circulating catecholamines, and these non-neuronal sites include the
lungs (Bryan-Lluka et al., 1992
) and the placenta (Ramamoorthy et al.,
1993
; Bzoskie et al., 1997
).
The human NET was the first monoamine neurotransmitter transporter for
which the primary structure was revealed by molecular cloning
(Pacholczyk et al., 1991
). The bovine NET, bNET1 (Lingen et al., 1994
),
and the murine NET (Fritz et al., 1998
) have subsequently been cloned
and sequenced. We recently reported the sequence of a full-length rat
NET cDNA from rat pheochromocytoma PC12 cells (Brüss et al.,
1997
); one of the aims of this study was to characterize this
transporter in more detail. The main aim of the study was a species
comparison of the pharmacological properties of the rat, human, and
bovine NETs by examining the properties of these transporters in COS-7
cells transfected with the appropriate NET cDNA. There are many
previous studies on the effects of drugs on the NET in rat tissues,
such as vas deferens (Bönisch et al., 1986
; Schömig et al.,
1989
), heart (Grohmann, 1987
; Schömig et al., 1989
), and lungs
(Bryan-Lluka et al., 1992
; Paczkowski et al., 1996
; Westwood et al.,
1996
), and in bovine adrenal medullary chromaffin cells (Bunn et al.,
1992
). Hence, it is important to know whether there are any differences
in the pharmacology of the rat and bovine NETs compared with the human
NET. The rat, human, and bovine NETs were studied in the same cell
system (i.e., COS-7 cells transiently expressing these transporters),
and 1) kinetics of [3H]norepinephrine uptake,
2) Ki values of a range of NET
substrates and inhibitors for inhibition of norepinephrine uptake, and
3) kinetics of stimulation by Na+ of
norepinephrine uptake were compared for the rat, human, and bovine NETs
expressed in the cells.
| |
Materials and Methods |
|---|
|
|
|---|
Cell Culture.
COS-7 cells (SV40-transformed African green
monkey kidney cells; American Type Culture Collection, Bethesda, MD)
were grown at 37°C in a 5% CO2, humidified
atmosphere on standard plastic cultureware in Dulbecco's modified
Eagle's medium (DMEM; GIBCO BRL Life Technologies, Gaithersburg, MD)
supplemented with 10% fetal calf serum (GIBCO BRL) and 100 U/ml
penicillin and 100 µg/ml streptomycin (GIBCO BRL) to obtain complete
DMEM. When the cells were confluent, subcultures were made using 0.25%
trypsin (Sigma Chemical Co., St. Louis, MO) at a ratio of 1:7 into
12-well plates, 2 days before transfection. The cells were transiently
transfected with the cDNA encoding either the rat NET (in the pEUK-C1
vector), human NET (in the pEUK-C1 vector), or bovine NET (in the pSG5 vector) or the pEUK-C1 vector (without insert) using Lipofectamine reagent (GIBCO BRL). Cloning of the transporter cDNAs into the pSG5 and
pEUK-C1 eukaryotic expression vectors has been described previously
(Lingen et al., 1994
; Brüss et al., 1997
). The transfection mixture containing 200 ng of cDNA and 2 µl of Lipofectamine in 500 µl of Opti-MEM (GIBCO BRL) was added to each well and incubated at
37°C in a 5% CO2, humidified atmosphere for
7 h. Complete DMEM supplemented with an additional 10% fetal calf
serum was then added to each well (500 µl). The transfection solution
was discarded 17 h later and replaced with complete DMEM.
Experiments were performed 24 h later.
Buffer for Incubation Experiments.
The Krebs/HEPES buffer
used in the experiments (unless otherwise indicated) contained 125 mM
NaCl, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 1.3 mM
CaCl2, 25 mM HEPES, 5.55 mM
D-(+)-glucose, 1.02 mM ascorbic acid, 10 µM U-0521 [to
inhibit catechol-O-methyltransferase (S-adenosyl-L-methionine:catechol-O-methyltransferase;
EC 2.1.1.6)], and 100 µM pargyline [to inhibit monoamine oxidase
(amine:oxygen oxidoreductase [deaminating] [flavin containing];
EC1.4.3.4)], and the pH was adjusted to 7.4 with NaOH (which added a
further 12.5 mM Na+). In experiments on the
kinetics of the sodium dependence of the NETs, the NaCl concentration
in the Krebs/HEPES buffer was 10, 20, 40, 80, or 160 mM, with 150, 140, 120, 80, or 0 mM LiCl added to maintain the same concentration of
Cl
in each solution, and the pH was adjusted to
7.4 with Tris.
Norepinephrine Uptake Assays.
DMEM was removed from the
cells, and they were washed twice with 1 ml of Krebs/HEPES buffer
containing 0.1% BSA at 37°C. The same buffer, where necessary
containing 1 µM nisoxetine or other drugs or ionic changes as
indicated, was then added to each well (1 ml) for 15 min at 37°C. The
cells were then incubated for exactly 2 min at 37°C with solutions of
the same composition but with 10 nM
[3H]norepinephrine added to determine initial
rates of norepinephrine uptake into the cells. The incubation solution
was then rapidly removed, and the cells were immediately washed three
times with 2 ml of ice-cold Krebs/HEPES buffer to terminate uptake and
remove extracellular amine. The cells were lysed by incubation with 1 ml of 0.1% Triton X-100 in 10 mM Tris · HCl, pH 7.5, for 60 min at
37°C. Determination of the protein content by the Lowry method (Lowry
et al., 1951
) was carried out on 100 µl of the lysate, and the
3H content of 800 µl of the lysate was
determined by the addition of 2 ml of Starscint scintillation medium
(Packard, Melbourne, Australia) and liquid scintillation counting.
Drugs and Solutions.
Citalopram hydrobromide was obtained
from Lundbeck (Copenhagen-Valby, Denmark). Cocaine hydrochloride was
purchased from Drug Houses of Australia (Sydney, Australia).
Desipramine hydrochloride, (
)-epinephrine bitartrate, imipramine
hydrochloride, (
)-norepinephrine bitartrate, and pargyline
hydrochloride were obtained from Sigma Chemical Co. U-0521
(3',4'-dihydroxy-2-methylpropiophenone) was obtained from Upjohn Pty.
Ltd. (Kalamazoo, MI). Fluoxetine hydrochloride and nisoxetine
hydrochloride were purchased from Lilly Research Laboratories
(Indianapolis, IN). GBR 12909 (1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride) and MPP+ iodide were purchased
from Research Biochemicals International (Natick, MA). (+)-Oxaprotiline
hydrochloride was obtained from Ciba-Geigy Ltd. (Basel, Switzerland).
Paroxetine hydrochloride was obtained from SmithKline Beecham
Pharmaceuticals (Worthing, West Sussex, UK). The radiolabeled
norepinephrine used in the experiments was
[ring-2,5,6-3H](
)-norepinephrine
(specific activity, 2100 Bq/pmol; NEN Life Science Products, Boston,
MA). Stock solutions of norepinephrine, epinephrine, and dopamine (10 mM) were prepared in 10 mM HCl, and stock solutions of the other drugs
were prepared in water as 10 mM solutions for all drugs except U-0521
and GBR 12909, which were prepared as 1 mM and 100 µM solutions,
respectively. All dilutions were prepared on the day of the experiment
in Krebs/HEPES buffer.
Calculation of Results.
The results of liquid scintillation
counting and protein determinations were used to calculate the
[3H]norepinephrine uptake into the cells,
expressed as fmol/mg protein. In each experiment, the mean result from
duplicate wells for each treatment was used. Specific uptake was
calculated as the difference between uptake of
[3H]norepinephrine in the absence (total
uptake) and presence (nonspecific uptake) of 1 µM nisoxetine for each
plate. The n values shown represent the number of different
experiments on separate plates for each treatment.
Km values of norepinephrine and of
Na+ for norepinephrine uptake by the NETs were
calculated from nonlinear regression analysis of the data for each
individual experiment according to a hyperbolic model.
IC50 values for inhibition of [3H]norepinephrine uptake by the drugs used in
the study were calculated from nonlinear regression analysis of percent
inhibition of specific uptake versus log drug concentration data for
each individual experiment according to a sigmoidal model and were used
to calculate the Ki value for each
drug in each experiment (Cheng and Prusoff, 1973
).
pKm and
pKi values were calculated as the
negative log of the corresponding Km
and Ki values expressed in molar
concentrations. Arithmetic mean ± S.E.M. or geometric mean values
and 95% confidence limits were calculated as indicated in
Results. The significance of differences between treatment
groups (e.g., inhibitors or species) was determined by the Student's
or paired t test or by one-factor repeated measures ANOVA
(because data for each treatment group or species were included in each
experiment) followed by Tukey-Kramer post hoc t tests as
indicated in Results. All data were analyzed using Prism 2 software (GraphPAD Software, San Diego, CA).
| |
Results |
|---|
|
|
|---|
Functional Properties of Rat NET.
When COS-7 cells were
transfected with the human NET cDNA or the rat NET cDNA that we
recently cloned from PC12 cells (Brüss et al., 1997
), there was
marked uptake of [3H]norepinephrine (969 ± 95 fmol/mg protein, n = 3, and 1159 ± 146 fmol/mg protein, n = 3, respectively) that was
inhibited in both cases by 98% in the presence of 1 µM concentration
of the NET inhibitor nisoxetine (P < .001). This
confirmed the functional expression of the NETs in our system. On the
other hand, control transfection of COS-7 cells with the vector pEUK-C1
and subsequent incubation with
[3H]norepinephrine resulted in only a very
small amount of norepinephrine accumulation (10.9 ± 1.71 fmol/mg
protein, n = 3) that was not significantly
affected by 1 µM nisoxetine.
Pharmacological Comparison of Rat, Human, and Bovine NETs.
Sequence alignment of the rat, human, and bovine NETs (Fig.
1) showed that there are five amino acid
exchanges that lead to changes in the local charge distribution in the
rat sequence compared with the species variants. To investigate the
potential effects of these amino acid exchanges, a comparison was made
of the kinetics of norepinephrine uptake by the rat, human, and bovine
NETs by incubating COS-7 cells expressing each of the NETs with 10 nM or 0.3, 1, 3, or 10 µM [3H]norepinephrine.
Uptake of [3H]norepinephrine by the NETs was
saturable (Fig. 2A), and the results of
the kinetic analyses are shown in Table
1. The Hill coefficients for all three
NETs were not significantly different from 1 (P > .05, Student's t test). The pKm
value of norepinephrine for the human NET was significantly greater
than that for the rat NET (Table 1), indicating a lower affinity of
norepinephrine for the rat NET than for the human NET. The
Vmax values for norepinephrine transport were 188 ± 22.5, 95.4 ± 8.62, and 141 ± 17.7 pmol/mg protein/min (n = 4) for the rat, human,
and bovine NETs, respectively. However, the meaning of differences in
these Vmax values is unclear because
they are dependent not only on the transporter but also on the vector
and transfection efficiency.
|
|
|
)-epinephrine (1, 3, 10, and 30 µM) and for the four inhibitors
nisoxetine (1, 3, 10, and 30 nM), desipramine (1, 3, 10, and 30 nM),
imipramine (10, 30, 100, and 300 nM), and cocaine (60, 200, 600, and
2000 nM). There were no significant differences between the
pKi values of dopamine for the three
NETs, but the pKi values for
MPP+ were greater for human NET than for rat NET
and the pKi values for epinephrine
were greater for human and bovine NETs than for rat NET (Table
2). It can be concluded that, as found
above for norepinephrine, MPP+ and epinephrine,
but not dopamine, have lower affinities for rat NET than for human
NET, and epinephrine also has a lower affinity for rat NET than for
bovine NET. For the inhibitors tested, the pKi value of cocaine was greater for
human and bovine NETs than for rat NET (Table 2), but there were no
significant differences between the three NETs for the
pKi values of nisoxetine, desipramine, or imipramine (Table 2). Hence, cocaine has a lower affinity for the
rat NET than for the human or bovine NETs, and there were no species
differences for the other inhibitors tested. As shown in Fig.
3, there is a marked correlation between
the pKi values for inhibition of rat
NET by the compounds and data obtained previously for inhibition of
uptake of norepinephrine in rat PC12 cells (Bönisch and Harder,
1986
|
|
|
| |
Discussion |
|---|
|
|
|---|
One aim of the study was to characterize in greater detail the
functional properties of the rat NET we recently cloned from rat PC12
cells (Brüss et al., 1997
). In transiently transfected COS-7
cells, [3H]norepinephrine uptake by rat NET was
inhibited by selective NET inhibitors and not to any marked extent by
selective SERT or DAT inhibitors; the
Km value of norepinephrine uptake and
the Ki values of NET substrates and
inhibitors were correlated with previous values in rat PC12 cells (Fig.
3), and the Km of
Na+ for stimulation of norepinephrine uptake was
comparable with that obtained previously in rat PC12 cells (Friedrich
and Bönisch, 1986
). Hence, the typical properties of the PC12
cell rat NET are not changed when this transporter is expressed in
non-neuronal cells such as COS-7 cells.
The main aim of the study was to examine species differences in the
pharmacological properties between the rat NET and the previously
cloned human and bovine NETs. In a study on SERT, tricyclic antidepressants were less potent, amphetamine was more potent, and
nontricyclic inhibitors showed no differences in potency for rat
compared with human SERT (Barker et al., 1994
). Furthermore, for DATs
expressed in COS-7 cells, binding of a cocaine analog and
MPP+ uptake decreased in the order human > rat > bovine (Lee et al., 1996
). These results suggest that small
interspecies differences in amino acid sequences of the monoamine
transporters are sufficient to result in significant functional
differences. The rat NET shows 93 and 91% amino acid identity to its
human and bovine counterparts, respectively (Brüss et al., 1997
).
Thus, we examined whether these small differences in amino acid
sequence might be sufficient to cause differences in their
functional and pharmacological properties.
The rat, human, and bovine NETs expressed in COS-7 cells showed, as
expected, Na+-dependent and saturable
norepinephrine uptake that was inhibited by NET substrates and
inhibitors. The Km value of
norepinephrine and the Ki values of
the substrates and inhibitors were comparable with those obtained in
previous studies with the human (Pacholczyk et al., 1991
; Pifl et al.,
1996
) and bovine (Lingen et al., 1994
) NETs, and there were highly
significant correlations between the values obtained for rat NET in
this study and those obtained previously in rat PC12 cells
(Bönisch and Harder, 1986
; Fig. 3) and perfused lungs
(Bryan-Lluka and O'Donnell, 1992
; Paczkowski et al., 1996
; r = 0.888, P < .01).
Experiments with a range of Na+ concentrations
showed that transport of norepinephrine by the three NETs is clearly
Na+-dependent and that the rat NET exhibits a
higher affinity for Na+ than the bovine NET. The
Hill coefficient of about 1 for the Na+
concentration dependence indicates that a single
Na+ ion is involved in transport by each of the
three NETs. These results are in accordance with previous studies on
the rat NET in PC12 cells (Friedrich and Bönisch, 1986
) and on
the heterologously expressed human NET (Gu et al., 1994
).
The interspecies comparison of the pharmacological properties of the three NETs showed that the Km or Ki values of three of the four substrates tested (norepinephrine, epinephrine, and MPP+) were greater, and hence their affinities were less, for the rat NET than the human NET, to a small but significant extent, but the Ki value of dopamine showed no species differences. The Ki values of the NET inhibitors nisoxetine, desipramine, and imipramine did not show any species differences, but the Ki value of cocaine was greater for the rat NET than for the human and bovine NETs, indicating a higher affinity of cocaine for the latter two NETs. It should be noted that the experimental design of the present study, in which strictly parallel experiments included each of the three NETs, provided a very sensitive experimental paradigm for the detection of small differences in the affinities of the compounds for the transporters. This was further aided by the high level of reproducibility (with small variances) of the pKm and pKi values presented in Tables 1 to 3.
The slightly higher affinities of the substrates tested (except
dopamine) for human NET than for rat NET contrasts with comparative data for SERT where substrate affinities generally did not differ between rat and human, except in the case of amphetamine, where rat
SERT had the higher affinity (Barker et al., 1994
). For inhibitors, there also were differences between the results obtained in the present
study for NET, where cocaine was the only inhibitor to show any species
differences in affinities (higher affinity for human and bovine than
for rat NETs), and the previous study with SERT, where tricyclic
antidepressants had markedly higher affinities for human than for rat
SERT and there was no difference for cocaine (Barker et al., 1994
). In
the present study, cocaine exhibited a significantly lower affinity for
the rat NET than for the bovine and human NETs. A similar species
difference in the affinity of cocaine was also shown previously for the
DAT, where the affinity of cocaine was lower for rat DAT than for human
DAT (Giros et al., 1992
). These differing species-dependent effects for
cocaine compared with other inhibitors are compatible with the
circumstantial evidence from NET/DAT chimera studies (Giros et al.,
1994
; Buck and Amara, 1995
) and site-directed mutagenesis studies on
the DAT (Kitayama et al., 1992
, 1993
) that the binding sites on the monoamine transporters for cocaine and its analogs are different from
those for other inhibitors, such as the tricyclic antidepressants.
For species homologs of receptors, relatively conservative mutations
close to the ligand-binding site have been shown to have marked effects
on ligand affinity, such as rat and human neurokinin NK1 receptors (Pradier et al., 1995
) and human
and rat 5-hydroxytryptamine1B receptors
(Oksenberg et al., 1992
). The three NETs compared in this study can be
regarded as naturally occurring variants of a common functional motif.
Alignment of the amino acid sequences of the rat, human, and bovine
NETs showed that of the amino acids that are divergent in rat NET but
are conserved between the human and bovine NETs (Fig. 1), five of them
in particular predict striking alterations in local charge distribution
and occur at positions that are conserved among the other cloned NETs
(Fig. 1). In addition, one of these exchanges results in loss of one
putative N-glycosylation site in rat NET compared with the
human and bovine NETs (Fig. 1). Interestingly, the mouse NET (Fritz et
al., 1998
) is identical with the rat NET at this position but identical
with the human and bovine transporters at the other four positions. It
is not possible to speculate from the data obtained in the present
study, even in combination with previous reports on chimeras of NET and DAT (Buck and Amara, 1994
, 1995
; Giros et al., 1994
), as to the particular amino acid exchanges that may contribute to the small, but
significant, species differences found in the affinities of substrates,
cocaine, and Na+ for the NETs.
In conclusion, we confirmed that the recently cloned rat NET
(Brüss et al., 1997
) shows the typical functional properties of a
NET. The fact that the affinities for some substrates, cocaine and
Na+ exhibited small, but significant,
interspecies differences among the rat, human, and bovine NETs suggests
that ligand recognition, the translocation process, and
Na+ dependence are influenced differentially by
just a few amino acid exchanges in the primary sequences of the
transporters. Site-directed mutagenesis studies should clarify whether
the amino acid differences between the NETs are responsible for the
observed small functional differences in the pharmacological properties
among the rat, human, and bovine NETs. On the other hand, the lack of
any major differences in the pharmacological properties of the rat,
human, and bovine NETs in this study suggest that data obtained in
previous studies on rat tissues and bovine cells should reflect, in all
but the most quantitative analyses, the properties of the human NET.
| |
Acknowledgments |
|---|
We thank Dr. Susan G. Amara (Vollum Institute, Oregon Health Sciences University, Portland, OR) for the donation of the human NET cDNA and acknowledge the donations of citalopram hydrobromide by Dr. J. Hyttel (Lundbeck Copenhagen-Valby), U-0521 by Dr. D. Woodhouse (Upjohn Company), paroxetine hydrochloride by Dr. P.G. Treagust (SmithKline Beecham Pharmaceuticals), nisoxetine hydrochloride and fluoxetine hydrochloride by Dr. M. H. Niedenthal (Lilly Research Laboratories), and (+)-oxaprotiline hydrochloride by Dr. L. Maître and Dr. H. Kaufmann (Ciba Geigy).
| |
Footnotes |
|---|
Accepted for publication April 7, 1999.
Received for publication December 24, 1998.
1
This study was supported by grants from the National
Health and Medical Research Council of Australia and the University of Queensland Round Three Quality Funds for International Research (L.J.B.-L.) and by Deutsche Forschungsgemeinschaft Grant SFB 400 A1
(H.B.). P.P. was a recipient of a graduate training fellowship from the
Deutsche Forschungsgemeinschaft (Graduiertenkolleg 246). Preliminary
results of this study were presented at the fall meeting of the German
Society for Experimental and Clinical Pharmacology and Toxicology
(Pörzgen et al., 1997
) and the December 1997 meeting of the
Australasian Society of Clinical and Experimental Pharmacologists and
Toxicologists (Paczkowski et al., 1997
).
Send reprint requests to: Dr. Lesley J. Bryan-Lluka, Department of Physiology and Pharmacology, The University of Queensland, Brisbane, Queensland 4072, Australia. E-mail: Lluka{at}plpk.uq.edu.au
| |
Abbreviations |
|---|
NET, norepinephrine transporter; DAT, dopamine transporter; DMEM, Dulbecco's modified Eagle's medium; GBR 12909, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-[3-phenylpropyl]piperazine dihydrochloride; MPP+, 1-methyl-4-phenylpyridinium ion; SERT, serotonin (5-hydroxytryptamine) transporter; TMD, transmembrane spanning domain; U-0521, 3',4'-dihydroxy-2-methylpropiophenone.
| |
References |
|---|
|
|
|---|
in transport.
Naunyn-Schmeideberg's Arch Pharmacol
333:
246-252[Medline].This article has been cited by other articles:
![]() |
M. I. Torres-Altoro, K. J. White, G. J. Rodriguez, D. E. Nichols, and E. L. Barker Helix XI contributes to the entrance of the serotonin transporter permeation pathway Protein Sci., October 1, 2008; 17(10): 1761 - 1770. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Platt, J. K. Rowlett, and R. D. Spealman Noradrenergic Mechanisms in Cocaine-Induced Reinstatement of Drug Seeking in Squirrel Monkeys J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 894 - 902. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Haunso and D. Buchanan Pharmacological Characterization of a Fluorescent Uptake Assay for the Noradrenaline Transporter J Biomol Screen, April 1, 2007; 12(3): 378 - 384. [Abstract] [PDF] |
||||
![]() |
C. Pifl, G. Nagy, S. Berenyi, A. Kattinger, H. Reither, and S. Antus Pharmacological Characterization of Ecstasy Synthesis Byproducts with Recombinant Human Monoamine Transporters J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 346 - 354. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Damaj, F. I. Carroll, J. B. Eaton, H. A. Navarro, B. E. Blough, S. Mirza, R. J. Lukas, and B. R. Martin Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors Mol. Pharmacol., September 1, 2004; 66(3): 675 - 682. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Sharpe, E. Palant, C. I. Schroeder, D. M. Kaye, D. J. Adams, P. F. Alewood, and R. J. Lewis Inhibition of the Norepinephrine Transporter by the Venom Peptide {chi}-MrIA: SITE OF ACTION, Na+ DEPENDENCE, AND STRUCTURE-ACTIVITY RELATIONSHIP J. Biol. Chem., October 10, 2003; 278(41): 40317 - 40323. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Bryan-Lluka, H. Bonisch, and R. J. Lewis {chi}-Conopeptide MrIA Partially Overlaps Desipramine and Cocaine Binding Sites on the Human Norepinephrine Transporter J. Biol. Chem., October 10, 2003; 278(41): 40324 - 40329. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||